|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Czaja AJ: Current management strategies
for hepatocellular carcinoma. Minerva Gastroenterol Dietol.
59:143–159. 2013.PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
6
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ogasawara S, Chiba T, Ooka Y, Kanogawa N,
Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka
O: Efficacy of sorafenib in intermediate-stage hepatocellular
carcinoma patients refractory to transarterial chemoembolization.
Oncology. 87:330–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto Y, Lin PJ, Beraldi E, Zhang F,
Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR and
Gleave M: siRNA lipid nanoparticle potently silence clusterin and
delay progression when combined with androgen receptor cotargeting
in enzalutamide resistant prostate cancer. Clin Cancer Res.
21:4845–4855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rubenstein M, Tsui P and Guinan P:
Treatment of prostate and breast tumors employing mono- and
bi-specific antisense oligonucleotides targeting apoptosis
inhibitory proteins clusterin and bcl-2. Med Oncol. 27:592–599.
2010. View Article : Google Scholar
|
|
10
|
Rull A, Martinez-Bujidos M, Perez-Cuellar
M, Pérez A, Ordóñez-Llanos J and Sánchez-Quesada JL: Increased
concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic
serum is paradoxically associated with decreased apoJ content in
lipoproteins. Atherosclerosis. 241:463–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Trougakos IP, Djeu JY, Gonos ES and
Boothman DA: Advances and challenges in basic and translational
research on clusterin. Cancer Res. 69:403–406. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trougakos IP, Lourda M, Antonelou MH,
Kletsas D, Gorgoulis VG, Papassideri IS, Zou Y, Margaritis LH,
Boothman DA and Gonos ES: Intracellular clusterin inhibits
mitochondrial apoptosis by suppressing p53-activating stress
signals and stabilizing the cytosolic Ku70-Bax protein complex.
Clin Cancer Res. 15:48–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li
X, Yin Z and Liang H: Secreted clusterin gene silencing enhances
chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2
pathways in vitro. Cell Physiol Biochem. 33:1162–1175. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koltai T: Clusterin: A key player in
cancer chemoresistance and its inhibition. Onco Targets Ther.
7:447–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
Wei Z, Zhai B, Kanwar JR, Jiang H, et al: Secretory clusterin
contributes to oxaliplatin resistance by activating Akt pathway in
hepatocellular carcinoma. Cancer Sci. 104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiu P, Xu Z, Liu F, Li Z, Li T, Zou F, Sun
X and Li J: Down-regulating sCLU enhances the sensitivity of
hepatocellular carcinoma cells to gemcitabine by activating the
intrinsic apoptosis pathway. Dig Dis Sci. 59:1798–1809. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhong J, Xiu P, Dong X, Wang F, Wei H,
Wang X, Xu Z, Liu F, Li T, Wang Y and Li J: Meloxicam combined with
sorafenib synergistically inhibits tumor growth of human
hepatocellular carcinoma cells via ER stress-related apoptosis.
Oncol Rep. 34:2142–2150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dong X, Li R, Xiu P, Dong X, Xu Z, Zhai B,
Liu F, Jiang H, Sun X, Li J and Qiao H: Meloxicam executes its
antitumor effects against hepatocellular carcinoma in
COX-2-dependent and -independent pathways. PLoS One. 9:e928642014.
View Article : Google Scholar
|
|
19
|
Zhen Y, Zhang W, Liu C, He J, Lu Y, Guo R,
Feng J, Zhang Y and Chen J: Exogenous hydrogen sulfide promotes C6
glioma cell growth through activation of the p38 MAPK/ERK1/2-COX-2
pathways. Oncol Rep. 34:2413–2422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W, Liu Z, Zhao C and Zhai L: Binding of
MMP-9-degraded fibronectin to β6 integrin promotes invasion via the
FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast
cancer. Oncol Rep. 34:1345–1352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng X, Zhou Y, Tian H, Yang G, Li C, Geng
Y, Wu S and Wu W: Sulforaphane inhibits invasion by phosphorylating
ERK1/2 to regulate E-cadherin and CD44v6 in human prostate cancer
DU145 cells. Oncol Rep. 34:1565–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng X, Li F, Wang P, Jia S, Sun L and Huo
H: Apelin-13 induces MCF-7 cell proliferation and invasion via
phosphorylation of ERK1/2. Int J Mol Med. 36:733–738. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shannan B, Seifert M, Leskov K, Willis J,
Boothman D, Tilgen W and Reichrath J: Challenge and promise: Roles
for clusterin in pathogenesis, progression and therapy of cancer.
Cell Death Differ. 13:12–19. 2006. View Article : Google Scholar
|
|
24
|
Sowery RD, Hadaschik BA, So AI, Zoubeidi
A, Fazli L, Hurtado-Coll A and Gleave ME: Clusterin knockdown using
the antisense oligonucleotide OGX-011 re-sensitizes
docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
BJU Int. 102:389–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muhammad LA and Saad F: The role of
clusterin in prostate cancer: Treatment resistance and potential as
a therapeutic target. Expert Rev Anticancer Ther. 15:1049–1061.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song HB, Jun HO and Kim JH, Yu YS, Kim KW,
Min BH and Kim JH: Anti-apoptotic effect of clusterin on
cisplatin-induced cell death of retinoblastoma cells. Oncol Rep.
30:2713–2718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang
Y, Gao D, Jiang K, Gu D, Shen Q, et al: Clusterin facilitates
metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular
carcinoma. Oncotarget. 6:2903–2916. 2015.PubMed/NCBI
|
|
28
|
Xiu P, Dong XF, Li XP and Li J: Clusterin:
Review of research progress and looking ahead to direction in
hepatocellular carcinoma. World J Gastroenterol. 21:8262–8270.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Niu ZH, Wang Y, Chun B, Li CX and Wu L:
Secretory clusterin (sCLU) overexpression is associated with
resistance to preoperative neoadjuvant chemotherapy in primary
breast cancer. Eur Rev Med Pharmacol Sci. 17:1337–1344.
2013.PubMed/NCBI
|
|
30
|
Hassan MK, Watari H, Han Y, Mitamura T,
Hosaka M, Wang L, Tanaka S and Sakuragi N: Clusterin is a potential
molecular predictor for ovarian cancer patient's survival:
Targeting clusterin improves response to paclitaxel. J Exp Clin
Cancer Res. 30:1132011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng W, Sai W, Yao M, Gu H, Yao Y, Qian Q
and Yao D: Silencing clusterin gene transcription on effects of
multidrug resistance reversing of human hepatoma HepG2/ADM cells.
Tumour Biol. 36:3995–4003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang Y, Liu F, Zheng C, Sun S and Jiang Y:
Knockdown of clusterin sensitizes pancreatic cancer cells to
gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer
Res. 31:732012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma G, Cai H, Gao L, Wang M and Wang H:
sCLU regulates cisplatin chemosensitivity of lung cancer cells in
vivo. World J Surg Oncol. 13:802015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang B, Liu ZM, Hao FG and Wang M:
siRNA-directed clusterin silencing promotes cisplatin antitumor
activity in human non-small cell lung cancer xenografts in
immunodeficient mice. Eur Rev Med Pharmacol Sci. 18:1595–1601.
2014.PubMed/NCBI
|
|
35
|
Huang H, Wang L, Li M, Wang X and Zhang L:
Secreted clusterin (sCLU) regulates cell proliferation and
chemosensitivity to cisplatin by modulating ERK1/2 signals in human
osteosarcoma cells. World J Surg Oncol. 12:2552014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong F, Tian H, Yan S, Li L, Dong X, Wang
F, Li J, Li C, Cao Z, Liu X and Liu J: Dihydroartemisinin inhibits
endothelial cell proliferation through the suppression of the ERK
signaling pathway. Int J Mol Med. 35:1381–1387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scherzad A, Steber M, Gehrke T, Rak K,
Froelich K, Schendzielorz P, Hagen R, Kleinsasser N and Hackenberg
S: Human mesenchymal stem cells enhance cancer cell proliferation
via IL-6 secretion and activation of ERK1/2. Int J Oncol.
47:391–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu SQ, Xu CY, Qin MB, Tan L, Zhuge CF,
Mao YB, Lai MY and Huang JA: Ginkgo biloba extract enhances
chemotherapy sensitivity and reverses chemoresistance through
suppression of the KSR1-mediated ERK1/2 pathway in gastric cancer
cells. Oncol Rep. 33:2871–2882. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang LJ, Han SX, Bai E, Zhou X, Li M, Jing
GH, Zhao J, Yang AG and Zhu Q: Dose-dependent effect of tamoxifen
in tamoxifen-resistant breast cancer cells via stimulation by the
ERK1/2 and AKT signaling pathways. Oncol Rep. 29:1563–1569. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chou TY, Chen WC, Lee AC, Hung SM, Shih NY
and Chen MY: Clusterin silencing in human lung adenocarcinoma cells
induces a mesenchymal-to-epithelial transition through modulating
the ERK/Slug pathway. Cell Signal. 21:704–711. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shim YJ, Kang BH, Jeon HS, Park IS, Lee
KU, Lee IK, Park GH, Lee KM, Schedin P and Min BH: Clusterin
induces matrix metal-loproteinase-9 expression via ERK1/2 and
PI3K/Akt/NF-κB pathways in monocytes/macrophages. J Leukoc Biol.
90:761–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
